loading page

Low-dose oral chemotherapy and crizotinib for the manifold manifestations of inflammatory myofibroblastic tumor in children
  • +9
  • SATISHKUMAR MEENA,
  • RAMYA UPPULURI,
  • HARIKA VARLA,
  • NIKILA RAVICHANDRAN,
  • KESAVAN MELARCODE RAMANAN,
  • Venkateshwaran Vellaichamyswaminathan,
  • RADHAKRISHNAN SATHEESAN,
  • RAJIV LAZARUS PADANKATTI,
  • ANNAPURNESWARI SUBRAMANYAN,
  • ANN KURIAN,
  • Srinivas S,
  • REVATHI RAJ
SATISHKUMAR MEENA
Apollo Hospitals Chennai
Author Profile
RAMYA UPPULURI
Apollo Speciality Hospital
Author Profile
HARIKA VARLA
Apollo Speciality Hospital
Author Profile
NIKILA RAVICHANDRAN
Apollo Speciality Hospital
Author Profile
KESAVAN MELARCODE RAMANAN
Apollo Speciality Hospital
Author Profile
Venkateshwaran Vellaichamyswaminathan
Apollo Speciality Hospital
Author Profile
RADHAKRISHNAN SATHEESAN
Apollo Hospitals Chennai
Author Profile
RAJIV LAZARUS PADANKATTI
Apollo Hospitals Chennai
Author Profile
ANNAPURNESWARI SUBRAMANYAN
Apollo Hospitals Chennai
Author Profile
ANN KURIAN
Apollo Hospitals Chennai
Author Profile
Srinivas S
Apollo Hospitals Chennai
Author Profile
REVATHI RAJ
APOLLO SPECIALITY HOSPITAL
Author Profile

Abstract

We present our experience in the management of children with inflammatory myofibroblastic tumor, a total of five children with two presenting with superior mediastinal syndrome and three with abdominal disease. We treated all children with a low-dose oral chemotherapy protocol, including prednisolone, 6-mercaptopurine, methotrexate, and celecoxib. Children with the mediastinal disease showed complete response with chemotherapy alone, while the child with sigmoid polyp is in remission with the chemotherapy post complete excision. We commenced two children with abdominal disease on crizotinib due to local recurrence with an adequate response. Long term follow-up and prolonged therapy are essential to sustain remission.